Granulomatous Hepatitis: Is It Bugs, Drugs, or Other Untoward Culprits?

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2024 Apr 16

PMID 38623150

Authors

Neil Shah

Elie G Dib

Nora Joseph

Robert J Fontana

Affiliations

Soon will be listed here.

References

Russo M, Hoofnagle J, Gu J, Fontana R, Barnhart H, Kleiner D . Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014; 60(2):679-86. PMC: 4110177. DOI: 10.1002/hep.27157. View

Lin L, Barkman H, Smit E, de Langen A, Steeghs N, Beijnen J . Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients. Ther Drug Monit. 2023; 46(1):73-79. PMC: 10769168. DOI: 10.1097/FTD.0000000000001120. View

Krelle A, Kalapurackal Mathai V, Kirkland G, Nott L, Jose M, Whale K . Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report. Cancer Rep (Hoboken). 2021; 5(7):e1520. PMC: 9327652. DOI: 10.1002/cnr2.1520. View

Spengler E, Kleiner D, Fontana R . Vemurafenib-induced granulomatous hepatitis. Hepatology. 2016; 65(2):745-748. PMC: 5182184. DOI: 10.1002/hep.28692. View

Long G, Flaherty K, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F . Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017; 28(7):1631-1639. PMC: 5834102. DOI: 10.1093/annonc/mdx176. View

Subbiah V, Kreitman R, Wainberg Z, Gazzah A, Lassen U, Stein A . Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023; 29(5):1103-1112. PMC: 10202803. DOI: 10.1038/s41591-023-02321-8. View

Planchard D, Besse B, Groen H, Hashemi S, Mazieres J, Kim T . Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol. 2021; 17(1):103-115. DOI: 10.1016/j.jtho.2021.08.011. View

Hayashi P, Lucena M, Fontana R, Bjornsson E, Aithal G, Barnhart H . A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022; 76(1):18-31. PMC: 9233102. DOI: 10.1002/hep.32327. View

Culver E, Watkins J, Westbrook R . Granulomas of the liver. Clin Liver Dis (Hoboken). 2019; 7(4):92-96. PMC: 6490265. DOI: 10.1002/cld.544. View

10.

Fontana R, Liou I, Reuben A, Suzuki A, Fiel M, Lee W . AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2022; 77(3):1036-1065. PMC: 9936988. DOI: 10.1002/hep.32689. View

11.

Vigano M, La Milia M, Grassini M, Pugliese N, De Giorgio M, Fagiuoli S . Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers (Basel). 2023; 15(6). PMC: 10046041. DOI: 10.3390/cancers15061766. View

12.

Homan M, Warrier G, Lao C, Yentz S, Kraft S, Fecher L . Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma. Front Oncol. 2022; 12:855794. PMC: 9538392. DOI: 10.3389/fonc.2022.855794. View

13.

Gouda M, Subbiah V . Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023; 8(2):100788. PMC: 9984800. DOI: 10.1016/j.esmoop.2023.100788. View

14.

Bala V, Mitsogianni M, Laschos K, Pliakou E, Lazaridi E, Lampropoulou D . Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature. Mol Clin Oncol. 2022; 16(5):99. PMC: 8985069. DOI: 10.3892/mco.2022.2532. View

15.

Welsh S, Corrie P . Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015; 7(2):122-36. PMC: 4346212. DOI: 10.1177/1758834014566428. View

16.

Tsung I, Dolan R, Lao C, Fecher L, Riggenbach K, Yeboah-Korang A . Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther. 2019; 50(7):800-808. DOI: 10.1111/apt.15413. View

17.

Ahmad J, Barnhart H, Bonacini M, Ghabril M, Hayashi P, Odin J . Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022; 76(5):1070-1078. PMC: 9018618. DOI: 10.1016/j.jhep.2021.12.043. View

18.

Kleiner D, Chalasani N, Lee W, Fontana R, Bonkovsky H, Watkins P . Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2013; 59(2):661-70. PMC: 3946736. DOI: 10.1002/hep.26709. View